Concord Medical Reports Financial Results for the First Half of 2021
BEIJING, Dec. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research, and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2021.
2021 First Half Highlights
Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "Our performance in the first half of 2021 is highlighted by very strong revenue growth across regions and business sections. These results represent a remarkable recovery from the impact of the pandemic on our business, demonstrating the resilience of our people, as well as their commitment to each other and our clients. We believe that the opening of our new hospital will continuously shift our income structure from network business to hospital business with higher income potential."
"The Company's Guangzhou Concord Cancer Center (the "Guangzhou Hospital") was officially opened in June 2021. We believe that this will expand the Company's income from hospital business."
"The Company also officially opened an internet hospital in May 2021. The internet hospital aims to provide a series of cancer care services, ranging from cancer prevention to post-treatment recovery, on the Company's online platforms. We believe that the internet hospital will expand the influence of the Company's brand among the prime target groups of patients."
"We have cultivated our Cloud System Solutions business for our network business and recently-established internet hospital. Besides, the preparation of the proton therapy system at the Guangzhou Hospital is nearly competed, which is expected to be the only proton therapy system in the Southern China in the next few years. With the gradual operation of the proton center to the mature stage, we believe that the Company's revenue can be improved in the next few years."
2021 First Half Financial Results
Net revenues from the network business were RMB128.7 million ($20.0 million), representing a 241.4% increase from net revenues of RMB37.7 million in the first half of 2020, primarily attributable to the Company's development of Cloud System Solutions of medical devices for its existing medical equipment and consumable sales services. With three centers closed in the first half of 2021, the Company operated a network of 24 centers in 18 cities in China as of June 30, 2021.
Cost of revenues of the network business was RMB95.7 million ($14.8 million), representing a 555.5% increase from RMB14.6 million in the first half of 2020, primarily attributable to the Company's business expansion on consumable sales services.
Gross profit from the network business was RMB33.0 million ($5.1 million), representing a 42.9% increase from RMB23.1 million in the first half of 2020. The gross profit margin of the network business for the first half of 2021 was 25.6%, compared to the gross profit margin of 61.3% for the same period last year.
Selling expenses of the network business were RMB8.3 million ($1.3 million), representing a 57.2% decrease from RMB19.4 million in the first half of 2020. Selling expenses as a percentage of net revenues from the network business was 6.5% in the first half of 2021, compared to 51.5% in the first half of 2020. The decrease in selling expenses of the network business was mainly due to the decrease in staff cost and advertisement and promotion expenses.
General and administrative expenses of the network business were RMB72.3 million ($11.2 million), representing a 27.1% increase from RMB56.9 million in the first half of 2020. General and administrative expenses as a percentage of net revenues from the network business were 56.2% in the first half of 2021, compared to 150.9% in the same period last year.
Comparing to RMB3.9 million in the same period last year, capital expenditures decreased to RMB103.8 million ($16.1 million) in the first half of 2021, primarily for procuring equipment for network centers.
Accounts receivable were RMB73.7 million ($11.4 million) as of June 30, 2021, compared to RMB61.9 million as of December 31, 2020. The average period of sales outstanding for accounts receivable (also known as "Days Sales Outstanding") was 219 days in the first half of 2021.
During the first half of 2021, the Company handled 4,230 patient treatment cases and 31,204 patient diagnostic cases, representing a 10.2% increase and a 22.9% decrease from the same period last year, respectively. The decreases in diagnostic and overall cases were mainly due to the influence of the COVID-19 pandemic.
Net revenues from the hospital business were RMB64.2 million ($9.9 million) in the first half of 2021, representing a 41.7% increase from net revenues of RMB45.3 million in the first half of 2020, mainly because the Company's operation of self-owned hospitals has gradually recovered from the adverse impact of the COVID-19 pandemic.
Cost of revenues of the hospital business in the first half of 2021 was RMB94.9 million ($14.7 million), representing a 32.2% increase from cost of revenues of RMB71.8 million in the first half of 2020, mainly because the labor cost increased for the preparation of the opening of Guangzhou Hospital, which has been in operation since June 2021.
Gross loss from the hospital business was RMB30.7 million ($4.8 million) in the first half of 2021, compared to RMB26.5 million in the same period last year. The gross loss margin of the hospital business for the first half of 2021 was 47.8%, compared to the gross loss margin of 58.5% for the same period last year.
Selling expenses of the hospital business were RMB5.4 million ($0.8 million) in the first half of 2021, representing an 100.0% increase from selling expenses of RMB2.7 million in the first half of 2020. Selling expenses as a percentage of net revenues from the hospital business was 8.3% in the first half of 2021, compared to 6.0% in the first half of 2020.
General and administrative expenses of the hospital business were RMB101.7 million ($15.7 million) in the first half of 2021, of which employee benefit expenses were RMB73.2 million ($11.3 million). In the same period of last year, general and administrative expenses of the hospital business were RMB77.5 million. The increase was mainly due to the increase in salary and rental fees for hospitals. General and administrative expenses as a percentage of net revenues from the hospital business was 158.5% in the first half of 2021, compared to 171.1% in the first half of 2020.
Comparing to RMB364.9 million in the first half of 2020, capital expenditures of the hospital were RMB310.6 million ($48.1 million) in the first half of 2021. The decrease was mainly related to the decrease in construction fees and medical equipment payment.
As of June 30, 2021, accounts receivable from hospital business were RMB12.5 million ($1.9 million), representing an 19.4% decrease] from accounts receivable of RMB15.5 million as of December 31, 2020. The number of Days Sales Outstanding was 76 days in the first half of 2021.
As of June 30, 2021, the Company had bank loans and other borrowings totaling RMB2.2 billion ($338.8 million).
The Guangzhou Hospital commenced operation in June 2021. The Guangzhou Hospital is situated in Sino-Singapore Guangzhou Knowledge City (the "Knowledge City"), Guangzhou's newest modern development district. The Guangzhou Hospital provides high-quality diagnostic imaging and treatment services, such as radiology, ultrasound and nuclear medicine, diagnosis and remote consultation, education and training, to all the medical institutions, premium clinics and medical institutions around the Knowledge City. Advanced imaging diagnostic equipment, such as CT, magnetic resonance, and PET-CT, have been installed in the Guangzhou Hospital. The Guangzhou Hospital will equip with the leading-edge image-guided ProBeam proton therapy system by Varian.
The Company's internet hospital obtained the licence in April 2021 and commenced operation in May 2021. The internet hospital aims to provide a series of cancer care services, ranging from cancer prevention to post-treatment recovery, on the Company's online platforms. Integrating the Company's newly established internet hospital with its conventional network business, the Company has developed Cloud System Solutions business that aims to provide comprehensive services for its patients and hospital clients.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider specializing in cancer care, research and prevention. The Company operates a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centres in China. The Company focuses on providing multidisciplinary cancer care approach in all areas of oncology services in its cancer hospitals. The Company also equips its hospitals with technologically advanced equipment such as the state-of-the-art proton therapy system in its cancer hospitals in Beijing, Shanghai and Guangzhou. As of June 30, 2021, the Company operated a network of 24 centers based in 18 hospitals, spanning over 18 cities across 12 provinces and administrative regions in China. To ensure the commitment to the highest level of clinical care for patients, the Company offers ongoing education and training for doctors and other medical professionals in its network hospitals and centres in both local and overseas medical institutions. For more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
About Non-GAAP Financial Measures
To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense. The Company believes excluding share-based compensation expense from its GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results, as such expense is not directly attributable to the underlying performance of the Company's business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expense are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of Adjusted EBITDA, which is defined in this announcement as net income plus interest, taxes, depreciation and amortization, and share-based compensation expenses and other adjustments. Other adjustments include foreign exchange gain (loss), net, loss on disposal of long-lived equipment, income from disposal of associate companies and other income. Furthermore, Adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.
SOURCE Concord Medical Services Holdings Limited
Company Codes: NYSE:CCM